FDA
-
-
-
-
-
-
-
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
-
-
-
-
-
-
-
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
-
-
-
-
-
-
-
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Continues to Remind Investors of The Ongoing Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Reminds Investors of The Securities Action That Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

